Scott Henry
About Scott Henry
Scott R. Henry, CFA, is an independent director of NexGel (NXGL), appointed on January 16, 2023 . He is 54 years old (as of April 30, 2025) and serves as Managing Director and Senior Research Analyst at Alliance Global Partners, with 20+ years covering pharma, biotech, and medical devices; he holds an MBA (with distinction) from Cornell and attended the University of Rhode Island . Henry has been recognized in the Wall Street Journal “Best on the Street,” Forbes/Zacks “Best Analysts” (drugs), and Forbes/StarMine earnings estimate accuracy rankings, with frequent media appearances (CNBC, MarketWatch, Bloomberg) .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Alliance Global Partners | Managing Director, Senior Research Analyst | Not disclosed | Capital markets expertise |
| ROTH Capital Partners | Senior Research Analyst | Not disclosed | Sell-side coverage in healthcare |
| Oppenheimer | Research/Analyst roles | Not disclosed | Sell-side coverage |
| Thomas Weisel Partners | Research/Analyst roles | Not disclosed | Sell-side coverage |
| ABN AMRO | Research/Analyst roles | Not disclosed | Sell-side coverage |
| Leerink Swann & Co. | Research/Analyst roles | Not disclosed | Sell-side coverage |
External Roles
| Organization | Role | Status | Notes |
|---|---|---|---|
| Alliance Global Partners | Managing Director, Senior Research Analyst | Current | Financial markets role; potential MNPI exposure mitigated by NXGL insider trading policy |
Board Governance
- Independence: Board determined Henry is an “independent director” under Nasdaq rules .
- Committees (as of April 30, 2025): Audit (Chair), Compensation (Member), Nominating & Corporate Governance (Member). Steven Glassman is Board Chair; Zeldis chairs Nominating; Stein chairs Compensation .
- Audit Committee financial expert: Henry qualifies per Item 407(d)(5)(ii) of Regulation S‑K .
- Attendance: In 2024, Board held six meetings and five unanimous written consents; no director attended fewer than 75% of meetings of the Board and committees . In 2023, Board held eight meetings; no director below 75% attendance .
- Executive sessions: Audit Committee meetings include executive sessions with auditors, financial management, and legal counsel each quarter .
- Insider trading policy: Prohibits short sales and hedging/monetization transactions for directors .
Fixed Compensation
| Year | Annual Cash Retainer ($) | Committee/Chair Fees ($) | Meeting Fees ($) | Notes |
|---|---|---|---|---|
| 2023 | — | Not disclosed for Henry | — | Option-only compensation for non-employee directors in 2023 |
| 2024 | — | Not disclosed for Henry | — | No cash fees; equity grants only |
Performance Compensation
| Grant Date | Instrument | Quantity | Exercise/Grant Price | Fair Value | Vesting | Notes |
|---|---|---|---|---|---|---|
| 2023-08-17 | Stock Options | 15,000 | $2.05/share | $30,750 | 3,750 vested 2023-09-30; 1,250 monthly Oct–Jun | Director annual grant |
| 2024-09-13 | Stock Options | 25,000 | $2.72/share | $67,875 | 6,250 vested 2024‑09‑30; ~2,084 monthly Oct–Jun; 2,078 in Jun (rounding) | Director annual grant |
| 2025 (intended) | Stock Options | 25,000 | FMV on grant date | Not disclosed | Monthly until 2026 annual meeting | Board intention for non-employee directors |
- Performance metrics: No director-specific performance metrics disclosed; director equity awards vest on service schedules. The 2019 LTIP permits performance awards, but no such metrics are reported for directors .
Other Directorships & Interlocks
- Public company board roles for Henry: None disclosed. Appointment 8‑K confirms no related transactions under Item 404(a) at time of appointment .
Expertise & Qualifications
- Financial expertise: Audit Committee Chair; “audit committee financial expert” designation .
- Credentials: CFA; MBA (Cornell) .
- Sector experience: 20+ years in pharmaceutical, biotech, medical devices coverage; recognized analytical performance .
Equity Ownership
| Metric | 2023-04-27 | 2024-04-29 | 2025-04-30 | 2025-10-20 (Record Date) |
|---|---|---|---|---|
| Common Shares Owned | 85,000 | 135,735 | 135,053 | 113,356 |
| Options (exercisable or within 60 days) | — | 15,000 | 40,000 | 52,500 |
| Warrants (currently exercisable) | — | 11,848 | 17,757 | 17,757 |
| Restricted Stock (vested or vesting within 60 days) | — | — | — | 2,085 |
| Total Beneficial Ownership (shares) | 85,000 | 162,583 | 192,810 | 185,698 |
| Ownership % of Outstanding | 1.51% (of 5,611,282) | 2.61% (of 6,227,624) | 2.50% (of 7,654,037) | 2.26% (of 8,142,766) |
| Hedging/Pledging | Hedging prohibited by policy; no pledging disclosed |
Insider Trades
| Filing Date | Transaction Date | Type | Shares | Price | Post-Transaction Holdings | Source |
|---|---|---|---|---|---|---|
| 2025-10-06 | 2025-10-02 | Sale | 825 | $2.50 | 120,531 | https://www.sec.gov/Archives/edgar/data/1468929/000149315225017160/0001493152-25-017160-index.htm |
| 2025-10-06 | 2025-10-03 | Sale | 7,175 | $2.5502 | 113,356 | https://www.sec.gov/Archives/edgar/data/1468929/000149315225017160/0001493152-25-017160-index.htm |
Note: Transactions reported on Form 4; holdings reflect “securitiesOwned” post-transaction per filing. Full insider trade dataset retrieved via insider-trades skill (33 records, 2023–2025).
Governance Assessment
-
Strengths: Independent director; Audit Chair and designated financial expert; strong attendance; equity-heavy director compensation (no cash fees) supports alignment; significant beneficial ownership (2.26–2.61% across 2023–2025 snapshots) .
-
Risks/Red flags to monitor:
- Potential information barrier risk due to concurrent sell-side analyst employment; mitigated by strict insider trading/hedging prohibitions and board’s independence determination .
- Director and executive participation in company unit offerings in 2024 (February, August, November) indicates insider capital support but represents related-party transactions overseen by Audit Committee policy; names/allocations not individually disclosed .
- Recent modest open-market sales in October 2025; sizes appear small relative to total holdings; continue monitoring for pattern changes (Form 4) [SEC Form 4 URLs above].
-
Committee effectiveness: Audit Committee mandate includes oversight of auditor independence, risk management, related-party transaction approval, and quarterly executive sessions—positive governance practices under Henry’s chairmanship .
-
Shareholder oversight: 2025 proxy included advisory say‑on‑pay and frequency (Board recommended triennial), indicating evolving governance practices; results not yet disclosed here .